Mass Spectrometry Metabolomics Based Biomarkers for Detection of Autism Spectrum Disorder from Patient Blood Samples – IMFAR 2014 [PDF]
Presented at the 2014 International Meeting for Autism Research in Atlanta, Georgia in May 2014.
The diagnosis of autism spectrum disorder (ASD) at the earliest age possible is important for initiating optimally effective intervention. Patients can be reliably diagnosed through behavioral testing at about 2 years of age. However, in the United States, the average age of diagnosis is around 4 years. Using a non-targeted mass spectrometry-based metabolomic analysis of blood plasma, we demonstrated that some features with differential abundance in ASD vs. TD patients (4-6 years old) can be used to derive classification models with 81% accuracy.
Posters & Publications
- The NPDX AA test can identify ~30% of children with #autism spectrum disorder (ASD) with an increased risk of an AS… https://t.co/R1s2P7oIdB4 hours ago
- The holidays, which can be overstimulating even for neurotypical people, are coming soon. Adults with #autism think… https://t.co/PSA0EFahUn7 hours ago
- Save yourself a phone call – learn from the list of questions and answers about the NPDX AA test, written to addres… https://t.co/UcVH5ssk0119 hours ago